In both the clinical and the experimental studies on breast carcinomas, as well as on some ovarian cancer cell lines, tumour response to trastuzumab was proportional to the levels of ERBB2 expression (Xu et al, 1999; Vogel et al, 2002). Here, ERBB2 is linked to neoplasm.